Table 3.
Effect of HFHFD Feeding on Plasma Cytokine Concentrations
| Cytokine concentrations in plasma | CD | HFHFD | P |
|---|---|---|---|
| IFNγ, pg/mL | |||
| 10–15 wk | 2.24 (2.24–2.24) | 2.24 (2.00–7.98) | .429 |
| 20–25 wk | 2.24 (2.24–3.49) | 2.24 (2.24–2.24) | .662 |
| 32 wk | 2.24 (2.24–2.86) | 2.24 (2.24–2.24) | .537 |
| IL5, pg/mL | |||
| 10–15 wk | 3.05 (2.15–3.20) | 3.00 (3.00–3.23) | 1.000 |
| 20–25 wk | 2.43 (2.15–2.49) | 2.15 (2.15–5.50) | .931 |
| 32 wk | 2.15 (2.15–2.15) | 3.32 (2.38–4.36) | .082 |
| TNFα, pg/mL | |||
| 10–15 wk | 2.47 (2.17–2.50) | 2.72 (3.00–5.41) | .247 |
| 20–25 wk | 3.51 (3.33–3.65) | 4.28 (2.89–5.58) | .662 |
| 32 wk | 3.30 (2.11–3.51) | 8.38 (6.47–9.31) | .030 |
| IL2, pg/mL | |||
| 10–15 wk | 2.04 (1.75–2.17) | 1.47 (1.00–2.94) | .662 |
| 20–25 wk | 4.83 (2.98–5.65) | 1.35 (1.07–3.19) | .177 |
| 32 wk | 1.20 (1.02–1.46) | 1.99 (1.44–2.94) | .177 |
| IL6, pg/mL | |||
| 10–15 wk | 2.51 (2.51–2.83) | 3.51 (4.00–15.74) | .126 |
| 20–25 wk | 8.47 (4.45–26.02) | 5.11 (4.56–31.84) | .792 |
| 32 wk | 4.58 (2.51–6.15) | 4.93 (3.93–9.83) | 1.000 |
| IL4, pg/mL | |||
| 10–15 wk | 1.62 (1.62–1.62) | 1.62 (2.00–1.62) | .662 |
| 20–25 wk | 1.62 (1.62–1.62) | 1.62 (1.62–1.62) | .662 |
| 32 wk | 1.62 (1.62–1.62) | 1.62 (1.62–1.71) | .429 |
| IL10, pg/mL | |||
| 10–15 wk | 7.21 (7.21–7.21) | 7.21 (7.00–7.21) | .662 |
| 20–25 wk | 18.22 (7.21–33.77) | 7.21 (7.21–7.21) | .177 |
| 32 wk | 7.21 (7.21–24.68) | 19.48 (7.91–29.83) | .537 |
| IL9, pg/mL | |||
| 10–15 wk | 1.08 (1.08–2.89) | 2.37 (2.00–2.58) | .792 |
| 20–25 wk | 2.25 (1.62–2.91) | 1.09 (1.08–7.92) | .429 |
| 32 wk | 1.08 (1.08–1.12) | 1.56 (1.33–1.97) | .126 |
| IL17A, pg/mL | |||
| 10–15 wk | 2.66 (2.66–2.66) | 2.75 (3.00–3.31) | .537 |
| 20–25 wk | 4.13 (3.77–5.59) | 2.66 (2.66–3.67) | .329 |
| 32 wk | 2.66 (2.66–5.00) | 4.35 (2.88–6.74) | .429 |
| IL17F, pg/mL | |||
| 10–15 wk | 1.58 (1.58–1.58) | 1.58 (2.00–1.58) | .662 |
| 20–25 wk | 1.86 (1.58–2.11) | 1.58 (1.58–1.58) | .177 |
| 32 wk | 1.58 (1.58–2.93) | 1.58 (1.58–2.36) | .792 |
| IL21, pg/mL | |||
| 10–15 wk | 3.02 (3.02–3.02) | 3.02 (3.00–3.02) | .662 |
| 20–25 wk | 3.02 (3.02–3.02) | 3.02 (3.02–3.02) | 1.000 |
| 32 wk | 3.02 (3.02–3.02) | 3.02 (3.02–3.02) | .662 |
| IL22, pg/mL | |||
| 10–15 wk | 8.26 (4.44–14) | 4.44 (4.00–5.69) | .329 |
| 20–25 wk | 9.28 (4.44–14.74) | 4.44 (4.44–4.44) | .126 |
| 32 wk | 4.44 (4.44–16.5) | 4.88 (4.44–5.42) | .792 |
| IL13, pg/mL | |||
| 10–15 wk | 5.12 (5.12–5.12) | 5.12 (5.00–5.12) | .662 |
| 20–25 wk | 5.12 (5.12–5.12) | 5.12 (5.12–5.12) | 1.000 |
| 32 wk | 5.12 (5.12–5.12) | 5.12 (5.12–5.12) | 1.000 |
NOTE. Data are presented as medians (interquartile range). Statistical analysis was performed with the Mann–Whitney U test. Significant P values are in bold.
IFNγ, interferon γ; TNFα, tumor necrosis factor α.